C‐Reactive Protein to Lymphocyte Ratio (CLR) and Lactate Dehydrogenase to Albumin Ratio (LAR) as Prognostic Biomarkers in Acral Melanoma: Association With Tertiary Lymphoid Structures and Immune Cell Infiltration
Cancer Medicine · 2025
DOI: 10.1002/cam4.71078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Donglin Kang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Melanoma, L-Lactate Dehydrogenase, C-Reactive Protein, Biomarkers, Tumor. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
To investigate the correlation between peripheral blood CRP‐to‐lymphocyte ratio (CLR) and lactate dehydrogenase‐to‐albumin ratio (LAR) levels, prognosis, and the tumor microenvironment (TME) in patients with acral melanoma (AM), with a focus on tertiary lymphoid structures (TLS) and immune cell infiltration.
Methods
A retrospective cohort of 36 patients with acral melanoma was included. Clinical data and hematological parameters were collected. The maturity of TLS, the proportion of immune cells, and their spatial distribution within the TME were assessed using H&E staining and multiplex immunofluorescence. Kaplan–Meier survival curves and Cox regression models were employed to examine the association between these indicators and patient survival. Non‐parametric tests and Spearman's correlation analysis were used to compare CLR and LAR levels across patients with different TLS maturity and immune infiltration statuses.
Results
Elevated levels of CLR and LAR in the blood are associated with poorer prognosis in patients with acral melanoma. The levels of CLR and LAR vary across patients with TLS of different maturities, and these levels decrease as TLS maturity increases. Additionally, CLR and LAR levels are significantly correlated with the proportions of CD4+ and CD8+ T cells in TME, with higher levels of CLR and LAR being linked to reduced immune cell infiltration.
Conclusion
Elevated CLR and LAR levels are associated with poorer prognosis in AM patients, and this relationship is closely linked to the maturity of TLS and the extent of immune cell infiltration within the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
- Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
ORCID-Profile: Donglin Kang, Rong Huang, Zhengyun Zou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Kang, D., Su, X., Wang, J., Zhao, L., Huang, R., & Zou, Z. (2025). C‐Reactive Protein to Lymphocyte Ratio (CLR) and Lactate Dehydrogenase to Albumin Ratio (LAR) as Prognostic Biomarkers in Acral Melanoma: Association With Tertiary Lymphoid Structures and Immune Cell Infiltration. Cancer Medicine. https://doi.org/10.1002/cam4.71078
Vancouver
Kang D, Su X, Wang J, Zhao L, Huang R, Zou Z. C‐Reactive Protein to Lymphocyte Ratio (CLR) and Lactate Dehydrogenase to Albumin Ratio (LAR) as Prognostic Biomarkers in Acral Melanoma: Association With Tertiary Lymphoid Structures and Immune Cell Infiltration. Cancer Medicine. 2025. doi:10.1002/cam4.71078
BibTeX
@article{Kang2025,
author = {Kang, Donglin and Su, Xinyu and Wang, Jiayu and Zhao, Lianjun and Huang, Rong and Zou, Zhengyun},
title = {C‐Reactive Protein to Lymphocyte Ratio (CLR) and Lactate Dehydrogenase to Albumin Ratio (LAR) as Prognostic Biomarkers in Acral Melanoma: Association With Tertiary Lymphoid Structures and Immune Cell Infiltration},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71078}
}
EUVIMED